Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Editor's Note
Recently the ADA and the AHA came together to adjust the guidelines in diabetes patients with cardiovascular problems. They have agreed that managing the cardiovascular problems should be the guiding light in overall patient care, and worrying about A1c levels is of less importance. This is especially true in older patients.
These guidelines are related to medication selection, and now more than ever the SGLT-2 inhibitors appear to be the best choice to address both issues. Be sure to check out this month’s features, and if you want to know even more about how these compounds address cardiovascular problems, then check out the Homerun Slides that our publisher Steve Freed featured in Tuesday’s clinical newsletter.
Dave Joffe
Editor-in-chief
The US Food and Drug Administration (FDA) has approved empagliflozin (Jardiance, Boehringer Ingelheim Pharmaceuticals Inc and Eli Lilly) for the new indication of improving survival in adults with type 2 diabetes and cardiovascular disease (CVD).
2016 could be remembered for the year when the diabetes class of drugs known as the SGLT-2 inhibitors has made a huge impact on the lives of those with type 2 diabetes today and into the future.
Never in the history of the treatment for diabetes have we seen a new drug entry that reduce the risk for dying for those with diabetes.
In this exclusive interview, Dr. Claude Lardinois discusses genetic risk factors for cardiovascular issues in diabetes patients, the impact of smoking on amputations, and why albumin is a driver of cardiovascular disease.